Exkivity Wins HTA Thumbs Up In England For Rare & Aggressive NSCLC
NICE Also Confirms Spravato Rejection
Executive Summary
The budget-neutral deal under which Takeda’s Exkivity was previously made available via the National Health Service is ending and being replaced by commercial supply at a confidential price.
You may also be interested in...
Project Orbis: More Cancer Drugs Available In Scotland Than England
The UK joined Project Orbis in 2021 with the aim of speeding up the regulatory process for promising cancer drugs, but fewer than half of the drugs licensed under this pathway are available on the NHS in England.
French Regulator At Odds With EMA Over Safety Restrictions For Pseudoephedrine
The product information for all pseudoephedrine-containing medicines in the EU will need to be updated, the European Medicines Agency said.
French Regulator At Odds With EMA Over Safety Restrictions For Pseudoephedrine
The product information for all pseudoephedrine-containing medicines in the EU will need to be updated, the European Medicines Agency said today.